Brief: Syndax Announces FDA Priority Review Of NDA For Revumenib
26/03/2024 20:29
March 26 (Reuters) - Syndax Pharmaceuticals Inc
SNDX.O :
* SYNDAX ANNOUNCES FDA PRIORITY REVIEW OF NDA FOR REVUMENIB
FOR
THE TREATMENT OF RELAPSED/REFRACTORY KMT2AR ACUTE LEUKEMIA
* SYNDAX PHARMACEUTICALS INC - PDUFA ACTION DATE SET FOR
SEPTEMBER
26, 2024
* SYNDAX PHARMACEUTICALS INC - NDA BEING REVIEWED UNDER
FDA'S
RTOR PROGRAM
Source text for Eikon: ID:nPn2WKsSGa
Further company coverage: SNDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Syndax Pharmaceuticals
See all newsBrief: Syndax Announces Topline Results From Maxpire Phase 2 Trial Of Axatilimab In Idiopathic Pulmonary Fibrosis
Syndax says mid-stage trial of lung disease treatment fails main goal, ends development
Syndax Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Brief: Syndax Pharmaceuticals Q2 Operating Income USD -39.995 Million